Two identically-designed , 6-month , randomized , double-blind trials evaluated PA32540 vs. EC-ASA 325 mg in a secondary cardiovascular disease prevention population taking aspirin 325 mg daily for 3 months and at risk for ASA-associated gastric ulcers ( GUs ) .